About Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889
Debt
Debt-to-Equity Ratio0.60%
Current Ratio3.89%
Quick Ratio3.85%
Price-To-Earnings
Trailing P/E Ratio41.91
Forward P/E Ratio-23.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$316.61 million
Price / Sales8.56
Cash Flow$0.4482 per share
Price / Cash42.08
Book Value$1.46 per share
Price / Book12.92
Profitability
EPS (Most Recent Fiscal Year)$0.45
Net Income$62.97 million
Net Margins19.89%
Return on Equity89.83%
Return on Assets17.39%
Miscellaneous
Employees255
Outstanding Shares143,730,000
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.27. The biopharmaceutical company earned $189.60 million during the quarter, compared to analysts' expectations of $173.11 million. Halozyme Therapeutics had a net margin of 19.89% and a return on equity of 89.83%. The firm's quarterly revenue was up 386.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.21) earnings per share. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What price target have analysts set for HALO?
8 brokerages have issued twelve-month price targets for Halozyme Therapeutics' shares. Their predictions range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $19.75 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), REGENXBIO (RGNX) and Adaptimmune Therapeutics (ADAP).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., Pres, CEO & Director (Age 55)
- Ms. Laurie D. Stelzer, Sr. VP, CFO & Principal Accounting Officer (Age 50)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)
- Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
- Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54)
Has Halozyme Therapeutics been receiving favorable news coverage?
News articles about HALO stock have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Halozyme Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.23 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $18.86.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.75 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Halozyme Therapeutics (NASDAQ:HALO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. Their average twelve-month price target is $19.75, suggesting that the stock has a possible upside of 4.72%. The high price target for HALO is $29.00 and the low price target for HALO is $7.00. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.38 | 2.38 | 2.33 | 2.43 |
| Ratings Breakdown: | 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.75 | $19.75 | $18.6667 | $16.7143 |
| Price Target Upside: | 4.72% upside | 2.65% upside | 2.78% downside | 4.33% downside |
Halozyme Therapeutics (NASDAQ:HALO) Consensus Price Target History
Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Halozyme Therapeutics (NASDAQ:HALO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Halozyme Therapeutics (NASDAQ HALO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 85.25%
Halozyme Therapeutics (NASDAQ HALO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/20/2015 | Laurie Stelzer | CFO | Buy | 10,000 | $17.24 | $172,400.00 | |  |
| 6/18/2015 | Kenneth J Kelley | Director | Sell | 20,000 | $21.00 | $420,000.00 | | |
| 9/16/2014 | David A Ramsay | CFO | Buy | 25,000 | $8.90 | $222,500.00 | | |
| 9/16/2014 | Helen Torley | CEO | Buy | 50,000 | $8.92 | $446,000.00 | | |
| 8/19/2014 | John Stuart Patton | Director | Sell | 75,000 | $9.96 | $747,000.00 | | |
| 5/15/2014 | Robert Engler | Director | Sell | 126,700 | $7.56 | $957,852.00 | 233,176 | |
| 9/16/2013 | John Stuart Patton | Director | Sell | 75,000 | $9.13 | $684,750.00 | 155,000 | |
| 8/19/2013 | H. Michael Shepard | VP | Sell | 10,000 | $7.11 | $71,100.00 | | |
| 8/14/2013 | Kathryn Falberg | Director | Buy | 100,000 | $6.82 | $682,000.00 | 280,000 | |
| 11/29/2012 | Robert Engler | Director | Buy | 15,000 | $5.57 | $83,550.00 | | |
| 11/14/2012 | James P Shaffer | VP | Buy | 20,000 | $5.22 | $104,400.00 | | |
| 11/13/2012 | Kathryn E Falberg | Director | Buy | 50,000 | $5.21 | $260,500.00 | | |
| 8/27/2012 | Kenneth J Kelley | Director | Buy | 20,000 | $5.70 | $114,000.00 | | |
| 8/13/2012 | Gregory Ian Frost | CEO | Buy | 2,000 | $5.50 | $11,000.00 | | |
(Data available from 1/1/2013 forward)
Halozyme Therapeutics (NASDAQ HALO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | MabVax Therapeutics (MBVX) Announces Results of Antibody Program in Three Poster Presentations at 2018 AACR Meetings
www.streetinsider.com - April 19 at 8:33 AM |
 | Canaccord Genuity Analysts Give Halozyme Therapeutics (HALO) a $16.00 Price Target
www.americanbankingnews.com - April 15 at 8:22 PM |
| Zacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Post Quarterly Sales of $29.54 Million
www.americanbankingnews.com - April 13 at 1:58 AM |
| Halozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 11 at 9:16 PM |
| Piper Jaffray Analysts Give Halozyme Therapeutics (HALO) a $20.00 Price Target
www.americanbankingnews.com - April 10 at 10:31 PM |
 | Abzena Notes Termination Of Agreement With Halozyme Therapeutics
www.lse.co.uk - April 10 at 8:49 AM |
 | Halozyme To Host First Quarter 2018 Financial Results Conference Call
finance.yahoo.com - April 10 at 8:49 AM |
 | BRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement
www.reuters.com - April 9 at 8:44 AM |
| Form DEFA14A HALOZYME THERAPEUTICS
www.streetinsider.com - April 6 at 5:26 PM |
| Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 5:38 PM |
| Halozyme Therapeutics (HALO) PT Raised to $18.00
www.americanbankingnews.com - April 1 at 9:46 AM |
| Halozyme Therapeutics (HALO) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 2:18 PM |
| $29.54 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - March 27 at 1:56 AM |
| Halozyme Therapeutics (HALO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 26 at 5:58 PM |
| Zacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Announce -$0.21 Earnings Per Share
www.americanbankingnews.com - March 25 at 11:14 PM |
| Halozyme Therapeutics (HALO) and Eisai (ESALY) Head-To-Head Survey
www.americanbankingnews.com - March 24 at 7:14 AM |
| Halozyme Therapeutics (HALO) Upgraded by TheStreet to "B-"
www.americanbankingnews.com - March 24 at 12:28 AM |
| Halozyme Therapeutics (HALO) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 23 at 7:56 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.
finance.yahoo.com - March 23 at 8:40 AM |
| Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
finance.yahoo.com - March 22 at 5:23 PM |
| Halozyme Therapeutics (HALO) to Present Data From Six ... - StreetInsider.com
www.streetinsider.com - March 16 at 8:38 AM |
| Halozyme Therapeutics (HALO) to Present Data From Six Nonclinical Studies at AACR
www.streetinsider.com - March 15 at 8:34 AM |
| Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
finance.yahoo.com - March 14 at 6:46 PM |
 | Global Antidiabetics Market Opportunities 2018: Eli Lilly, Boehringer Ingelheim, Novo Nordisk
www.marketwatch.com - March 14 at 9:00 AM |
| QCOM Jeffrey William Henderson Insider Trades for Qualcomm Inc.
www.marketwatch.com - March 13 at 7:05 PM |
| Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 10 at 5:41 PM |
| Analysts Anticipate Halozyme Therapeutics, Inc. (HALO) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - March 8 at 4:15 PM |
| Senzar Asset Management LLC Has $10.89 Million Position in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - March 5 at 3:44 PM |
| Halozyme Therapeutics, Inc. (HALO) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 5 at 11:39 AM |
| 97,707 Shares in Halozyme Therapeutics, Inc. (HALO) Purchased by Schroder Investment Management Group
www.americanbankingnews.com - March 5 at 9:40 AM |
| Halozyme Therapeutics, Inc. (HALO) Stake Raised by Lombard Odier Asset Management Switzerland SA
www.americanbankingnews.com - March 4 at 2:39 PM |
| State of Wisconsin Investment Board Increases Stake in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - March 4 at 9:32 AM |
| Halozyme Therapeutics, Inc. (HALO) Position Lifted by Swiss National Bank
www.americanbankingnews.com - March 3 at 7:34 AM |
| Bogle Investment Management L P DE Acquires New Stake in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - March 3 at 4:52 AM |
| Sei Investments Co. Reduces Stake in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - March 2 at 7:06 AM |
| Snyder Capital Management L P Has $47.95 Million Stake in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - March 1 at 7:02 PM |
 | Technical Perspectives on Biotech Stocks -- Global Blood Therapeutics, GlycoMimetics, Halozyme Therapeutics, and Idera Pharma
www.prnewswire.com - March 1 at 6:46 AM |
| Halozyme Therapeutics, Inc. (HALO) Shares Sold by Brown Advisory Inc.
www.americanbankingnews.com - March 1 at 5:16 AM |
| Schwab Charles Investment Management Inc. Purchases 90,500 Shares of Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - February 28 at 5:44 AM |
| The Manufacturers Life Insurance Company Reduces Holdings in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - February 27 at 4:13 PM |
| Halozyme Therapeutics (HALO) Upgraded at BidaskClub
www.americanbankingnews.com - February 24 at 11:58 AM |
| Halozyme Therapeutics, Inc. (HALO) to Post Q1 2018 Earnings of ($0.28) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - February 23 at 8:06 AM |
| Halozyme Therapeutics, Inc. Forecasted to Post FY2022 Earnings of $0.69 Per Share (HALO)
www.americanbankingnews.com - February 22 at 4:34 PM |
| Halozyme Therapeutics (HALO) Price Target Increased to $19.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - February 22 at 3:20 PM |
 | Surface Oncology Expands Board of Directors
www.bizjournals.com - February 22 at 8:36 AM |
| Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology
finance.yahoo.com - February 22 at 8:36 AM |
 | Halozyme Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 21 at 5:16 PM |
| Halozyme Therapeutics (HALO) Given New $21.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - February 21 at 3:46 PM |
| Halozyme Therapeutics (HALO) Price Target Raised to $22.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - February 21 at 12:45 PM |
| Halozyme Therapeutics (HALO) Posts Quarterly Earnings Results, Beats Expectations By $0.27 EPS
www.americanbankingnews.com - February 21 at 9:21 AM |
Halozyme Therapeutics (NASDAQ:HALO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Halozyme Therapeutics (NASDAQ:HALO) Income Statement, Balance Sheet and Cash Flow Statement
Halozyme Therapeutics (NASDAQ HALO) Stock Chart for Sunday, April, 22, 2018
Loading chart…
